Risk factors

Company transitioned from electric vehicle manufacturing to digital asset treasury and stablecoin management during 2025. Financial results now depend entirely on volatile digital assets, market liquidity, and capital raising.

Going concern doubt intensified with operating cash outflows rising to $26.0 million for 2025.

Fermi Inc. is a development-stage company with no revenue, relying on capital raises to fund Project Matador, a multi-billion-dollar hybrid infrastructure site. The company faces execution risks across nuclear and natural gas power generation, data center leasing, and complex regulatory approvals.

Legal and antitrust pressures surrounding broker commissions and agent classifications intensified significantly this year.

GBank faces heavy geographic concentration in Las Vegas and Clark County, Nevada, exposing its real estate portfolio to regional economic downturns.

The company abandoned its first-generation international product and CE Mark, pivoting focus to the new Glucotrack CBGM product under preclinical development in the U.S.

Genprex relies heavily on ongoing equity sales under its ATM agreement to fund operations into the second quarter of 2027.

Net losses widened significantly to $2,982,333 in 2025, intensifying going concern doubts. The company faces severe dilution from a proposed issuance of 8,500,000 shares for the Forekast share exchange. New operational and regulatory risks target digital asset custody, exchange activities, and Nasdaq low-price delisting rules.

Hennessy Capital Investment Corp. VIII is a newly formed blank check company seeking an initial business combination focused on industrial innovation and energy transition sectors within 24 months. The company faces significant dilution risks from founder shares bought for $25,000 and potential conflicts of interest as management allocates time to other entities.

The company’s risk profile has shifted from biotech commercialization and financing to a concentrated HYPE-token treasury strategy.

Re-Tain® strategy shifted from internal manufacture toward licensing, sale, or partnership after abandoning planned production.

IMSR commercialization depends on completing design, licensing, manufacturing, construction and cost competitiveness.